PRQR Stock Analysis: Buy, Sell, or Hold?
PRQR - ProQR Therapeutics N.V. Ordinary Shares
$1.33
-0.08 (-5.67%)
▼
5d:
-7.64%
30d:
-18.4%
90d:
-29.07%
HOLD
LOW Confidence
Analysis Updated: Nov 5, 2026 12:00 AM ET
Earnings: Nov 05, 2026
0d
Get Alerted When PRQR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PRQR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: PRQR shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: PRQR is currently trading at $1.33, which is considered oversold relative to its 30-day fair value range of $1.33 to $1.61.
Technical Outlook: Technically, PRQR is in a downtrend. Immediate support is located at $1.20, while resistance sits at $1.50. Short-term momentum is weak, with the stock down 5.7% recently.
Market Sentiment: PRQR scores 80/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.78 (+484.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PRQR is in a downtrend. Immediate support is located at $1.20, while resistance sits at $1.50. Short-term momentum is weak, with the stock down 5.7% recently.
Market Sentiment: PRQR scores 80/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.78 (+484.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.33 -
$1.61
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
91.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (80/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.7%)
- BULLISH: Trading 484.8% below Wall St target ($7.78)
- BULLISH: Bottoming setup score 80/100 — corrected, stabilizing, and turning up
- CAUTION: Recommendation downgraded due to -7.6% 5-day decline
Trading Range Analysis
30-Day Trading Range
$1.33 -
$1.61
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.24
(17.8%)
Support & Resistance Levels
Support Level
$1.20
Resistance Level
$1.50
Current Trend
Downtrend
Technical data as of
Nov 5, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.87
Wall Street Target
$7.78
(+484.8%)
Revenue Growth (YoY)
120.4%
Profit Margin
-228.2%
Share & Embed Analysis
Last updated: November 06, 2026 5:32 AM ET
Data refreshes hourly during market hours. Next update: 6:32 AM
Data refreshes hourly during market hours. Next update: 6:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PRQR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
23 analysts |
$107 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$194 | 33 SELL |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$685 | 47 HOLD |
|
IMNM
Immunome Inc |
STRONG BUY
17 analysts |
$35 | 55 HOLD |
|
RCUS
Arcus Biosciences Inc |
STRONG BUY
15 analysts |
$41 | 64 BUY |
